Now approved
in the U.S.

EMPAVELI (pegcetacoplan) injection 1080mg / 20mL solution

Please see full Prescribing Information, including Boxed WARNING and Medication Guide.

US-CORP-2100013, v1.0, 05/14

Fearlessly Advancing


the first potential treatment
in geographic atrophy

Learn More
Leaders in Complement


at the forefront of targeted
C3 therapies

Learn More

With courageous science, creativity, and compassion,
we are committed to delivering therapies for people with
complement-driven diseases.

About Us
Folded page of a newspaper

Latest news

June 30, 2021

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases

June 23, 2021

Apellis Pharmaceuticals to Host R&D Day on June 30, 2021

June 3, 2021

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

A man with a baby in a baby carrier

At the heart of our company is the belief that exceptional science and compassion are not mutually exclusive.

Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

Our groundbreaking science

targeting C3 offers the potential to provide comprehensive control of complement, a part of the immune system

Our Science
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

We aim to transform

treatment across a broad range of debilitating diseases driven by complement